Draft:Geneyx

• Comment: Editor: you have zero references. Please very carefully read WP:VERIFY. Qcne (talk) 09:21, 31 August 2023 (UTC)

---

1

{{Connected contributor(paid)|User1=RavivItzhaky|U1-employer=Geneyx}}.

History

Geneyx is a clinical genetics data management platform, headquartered in Herzliya, Israel, and has a subsidiary in Delaware, USA. Geneyx provides genetic diagnosis and research services to hospitals, laboratories, and pharmaceutical industries. Geneyx Analysis is used to interpret whole genome sequencing, exome sequencing, long-reads, short-reads, carrier screening, pharmacogenomics, and gene panels.

In order to use the Geneyx platform, DNA is extracted from a patient sample and then enriched. This enriched DNA is then sequenced using a Next-Generation Sequencing (NGS) machine. Once the sequencing process is complete, the genomic data is digitized and uploaded. Next the analysis of genetic data, to identify unique genetic variants.The solution also provides insights into potential disease-causing mutations and novel drug discovery.

History

Geneyx Genomex (Geneyx) was established in 2018 as a Tel Aviv, Israel-based startup by co-founders David Yizhar, Raviv Itzhaky, Dvir Dahary, Ofer Yizhar, and Avi Yitzhak after acquiring TGex. In 2021 Geneyx raised $10 million in a seed round led by Capri Ventures and Accenture Ventures.

Geneyx partnered with Oxford Nanopore[1]and Pacific Biosciences[2] (PacBio) in 2023 to develop a new platform to provide end-to-end analysis and clinical reporting of nanopore sequencing with a simple "one-click" process. One of the main reasons for the Oxford Nanopore and Geneyx collaboration is the ability of Geneyx to analyze long-read sequencing and handle long data sets, including previously challenging-to-sequence regions.  

In 2023, the Bird Foundation[3] granted Geneyx and Ocean Genomex funding to collaborate. Their joint effort focused on creating a product that combines RNA sequencing from Ocean Genomics with DNA sequencing from Geneyx.

Notable discoveries:

*ECEL1, c.232+1del variant in the CEP85L gene

*2c.274A > G; p.Ser92Gly, NM_024516.4 in PAGR1, a gene not previously associated with a Mendelian disease. PAGR1 a gene currently not associated with a Mendelian disease.  

*Exon 5 in the PRKN gene and a common 49 kb deletion found in a heterozygous state in the normal sibling.  

*Two BMPR1A gene 11-exon deletions and a short BMPR1A indel variant.  

*Simultaneous inactivation of the SCN1A, SCN2A genes.  

*Biallelic loss of function variants in WBP4.  

Partnerships  

2017, Geneyx announced the acquisition of TGEX (TechGenomics).  

2022, Accenture and Geneyx signed a master agreement that recognizes Geneyx is a certified supplier of Accenture. The agreement also acknowledges that Accenture is an investor in Geneyx.  

April 2023, The contract was entered into between Geneyx Genomex Ltd and UHN (Toronto General Hospital). The objective is to conduct cohort analysis on specific data related to five different cardiovascular diseases.

In 2023, Geneyx Genomics collaborated with Oxford Nanopore[1], including Long-Read sequencing analysis.

In 2023, Genex Genomex formed a partnership with Pacific[2].

2023, G42 is a cloud computing company in the United Arab Emirates (UAE). G42 is collaborating on the 1 Million Genome Project. This global project aims to create a comprehensive genomic database by sequencing one million genomes from diverse populations worldwide. Geneyx Genomex was awarded the bid to analyze more than 400 000 genomes, making this the most extensive database in the world for 1 population.

Customers:

Bambino Gesu (Rome), Hadassah Ein-Kerem (Jerusalem) , Juno Genetics (NY/Oxford/Porto), Arcensus (Berlin), LifeCell (India) , Mediclinic (Abu-Dahabi)